SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as community members highlight its recent CEX listing and upcoming staking app with burns, which could drive further value. The community, self-proclaimed 'Brokies,' are actively discussing holding strategies and celebrating the project's growth, emphasizing a grind mentality. Despite market dips, the focus remains on building wealth and utilities for the BROKE.X token.

WorldFinancial

WLFI.X is trending as the community discusses its potential, real-world asset tokenization, and the impact of key figures like Justin Sun and the Trump family. Community members are actively monitoring price movements and anticipating future developments, with some focusing on potential short squeezes. The conversation also includes speculation around upcoming announcements and the rollout of new products.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X, a meme coin on the Bitcoin blockchain launched with the Runes protocol, is trending as community members highlight its fair distribution and potential to outperform other meme coins due to its Bitcoin-native nature. Discussion emphasizes its strong community, utility for Bitcoin miners, and the backing of a publicly listed company, $CBLO. Some users express concerns about volatility and limited exchange availability, while others anticipate significant growth and potential listings on major exchanges.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as traders discuss its potential as the next big memecoin on the Bitcoin network, emphasizing its community-driven nature and fair distribution. Some community members are anticipating upcoming tier 1 exchange listings and are drawing comparisons to the early days of Dogecoin. Meanwhile, other traders are using $DOG as a hedge, citing macroeconomic concerns and potential market corrections.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the U.S. Department of Commerce selected it to verify and distribute economic data on-chain, marking a significant step in institutional adoption of decentralized infrastructure. The community is discussing the potential impact of this partnership and Pyth's role in the evolution of digital transparency, with some drawing comparisons to Chainlink and speculating on future price movements.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending amid discussions around a potential share buyback program and its impact on the stock's valuation, with community members debating whether the company is undervalued. Some are analyzing technical indicators and expressing optimism for a rebound, while others focus on Briumvi's market potential and speculate on possible buyout scenarios. Chatter also revolves around management's strategy, upcoming presentations, and how the company is addressing analyst forecasts.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as community members express excitement about recent gains and speculate on future potential, with some drawing comparisons to XRP ($XRP.X). Community members are actively discussing where to purchase the token and highlighting its potential as a real-world asset (RWA).

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending as investors discuss the potential of its RNAi pipeline and upcoming catalysts, including the anticipation of key data readouts. Community talking points revolve around the company's strategic partnerships, potential for acquisitions, and comparisons to sector peers. Recent financial results and presentations have also sparked renewed interest in ARWR.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors assess its potential amid both positive developments, like the upcoming R2 SUV launch, and persistent concerns around profitability and cash burn. Community discussions revolve around potential breakouts, short positions, and the company's long-term vision compared to competitors like Tesla. Some traders are also reacting to news of layoffs and production adjustments.

The ArcBlock project was created to create the first Blockchain ecosystem in the world. Develop and develop decentralized applications (DApp) according to objectives. ArcBlock, one of the ICO projects emerging in early 2018. Just launched on 3/1/2018, ArcBlock has quickly attracted the attention of technology as well as investors. ArcBlock brings great technological advancements that will open the third generation of blockchain applications.  Arcblock work by bridging the gap between different blockchains and their respective ecosystems has not been easy. There are some solutions which attempt to solve this problem, but it is evident there is plenty of room for competition in this regard. Building an open chain access layer capable of spanning multiple new and existing blockchains is a very interesting business model.  Building a new ecosystem meant to connect various chains will not be easy. As of right now, the team has completed its token sale, and the first public release candidate for the Open Chain Access Protocol will be released in Q3. Early 2019 will herald the introduction of more technical features and an Ethereum Blocklet prototype.

ABT.X is trending with mixed sentiment as the community debates its potential amid fluctuating prices. Some traders are pointing to a recent volume increase and potential breakout points, while others express frustration with its performance and question its utility. Discussions include possible partnerships and price predictions, though many remain skeptical of its long-term prospects.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor...

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

<a href="https://stocktwits.com/symbol/JANX">Shares of Janux Therapeutics</a> Inc. surged over 54% on Tuesday afternoon, reaching levels not seen since May and breaking a five-day losing streak.&nbsp;The rally followed the company’s Monday announcement of promising Phase I trial data for its prostate cancer treatment, JANX007.In the trial, all 16 heavily pre-treated patients demonstrated a reduction of at least 50% in prostate-specific antigen (PSA) levels, a key indicator of cancer.&nbsp;The news sparked a wave of bullish analyst notes and retail investor enthusiasm.Stifel raised its price target to $115 from $70, citing increased probabilities of success for JANX007 in second- and third-line metastatic castration-resistant prostate cancer.&nbsp;The brokerage now forecasts $1.7 billion in risk-adjusted sales from these indications.&nbsp;Leerink boosted its price target to $91, highlighting the treatment’s “best-in-class” safety and efficacy profile.Cantor Fitzgerald took an even more optimistic stance, doubling its price target to $200. The brokerage praised JANX007 for achieving “unprecedented” PSA50 and PSA90 response rates while maintaining a tolerable safety profile.&nbsp;H.C. Wainwright also raised its target, albeit more modestly, to $70, increasing its probability of launch for JANX007 to 26% from 20%.<figure class="image"><a href="https://stocktwits.com/symbol/JANX"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/JANX_sentiment_and_message_volume_on_Dec_3_f914cb43e0.png" alt="JANX sentiment and message volume on Dec 3.png" width="1318" height="318"></a><figcaption>JANX sentiment and message volume on Dec 3 as of 2:15 pm ET | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned ‘extremely bullish’ amid a sharp increase in message volume, with many users seeing the breakthrough as a major milestone.&nbsp;The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.Janux has selected two once-weekly dose regimens for expansion trials targeting patients with two or three prior lines of therapy.&nbsp;The stock, up 460% year-to-date, is reportedly on track for its best year ever.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gm-stock-dips-after-plan-to-sell-battery-plant-stake/cJ9NCvaRhn">GM Stock Suffers Despite Battery Plant Stake Sale Plan: Retail Sentiment Dips To 5-Month Low</a>

Janux's stock, up 460% year-to-date, is reportedly on track for its best year ever.

Janux Therapeutics Stock Hits 7-Month High On Prostate Cancer Drug Trial Data: Retail Confidence Spikes

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.

Equity

The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.


Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Navigating 5 Analyst Ratings For Janux Therapeutics

Latest Ratings for JANX
 DateFirmActionFromTo Jul 2021B of A SecuritiesInitiates Coverage OnBuy Jul 2021Cowen & Co.Initiates Coverage OnOutperform Jul 2021HC Wainwright & Co.Initiates Coverage OnBuy...

Analyst Expectations For Janux Therapeutics's Future

Janux Therapeutics Announces Updates to Board of Directors

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb PR Newswire VANCOUVER, BC, May 9, 2024 USA...

Janux Therapeutics, Inc. operates a preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded by David Campbell in June 2017 and is headquartered in San Diego, CA.

JANX
Janux Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JANX News

JANX Janux Therapeutics Inc